SBIR/STTR Research Award
Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms
Award amount
$400,000Program and phase
STTR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- THERATARGET, INC.
- Proposal award date
- 2017-08-15
- Contract end date
- 2020-01-31
- UEI
- KGMNGV6P8533
- Solicitation number
- PA16-303
- Topic code
- 106
Research abstract
NARRATIVE
This STTR Phase I proposal details the rationale and the research plan for the development of a novel liquid
embolizing agent composed of the genetically engineered protein polymerSELPsilk elastinlike
proteinKto embolize cerebral aneurysmsThe SELP embolic would reduce the risk of aneurysm
rupture while minimizing the risk of recanalization after treatment and providing a platform for delivering
newly developed drugs or cell therapies directly to the aneurysmal sacThis work will result in an embolic that
can potentially improve aneurysm healingdeliver therapeutics locallyand reduce the risks associated with the
embolization of cerebral arteries
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma
- Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer
- In-situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma
- Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer
- Targeted Polymeric Combination Delivery for Treatment of Ovarian Cancer
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Clinical Validation of Myoelectric Implant for Intuitive Prosthesis Control
- Targeted ColQ gene therapy for Congenital Myasthenic Syndromes
- Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy
- Developing closed-loop tonic motor activation therapy for treatment of refractory restless legs syndrome
- Engineered microglia for the treatment of Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
Research funding history
6 SBIR/STTR records share this UEI (2010–2017). Reported award amounts total $3,239,367. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services